Archive: July 2024
Feature Article
Uterine Serous Carcinoma and Uterine Carcinosarcoma: Molecular Features, Clinical Advances, and Emerging Therapies
Abstract: Endometrial cancer, including high-grade subtypes, has a rising incidence and mortality. Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) make up a small but increasing […]
Advances in LLM
Pilot Data on Axicabtagene Ciloleucel for CNS Lymphoma
H&O Could you describe the impetus for and design of your pilot study on axicabtagene ciloleucel for CNS lymphoma? CJ When lymphomas that involve the central […]
Lung Cancer in Focus
Can Unresectable Non–Small Cell Lung Cancer Become Resectable?
H&O What is the definition of resectable disease in non–small cell lung cancer (NSCLC)? JC The definition of resectable disease is based on the determination of […]
Breast Cancer In Focus
Update on CDK4/6 Inhibitors in Breast Cancer
H&O Which breast cancer patients are eligible for treatment with a CDK4/6 inhibitor? ST CDK4/6 inhibitors, which include palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib […]
CLL
The Approval of Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia
H&O When did lisocabtagene maraleucel first receive approval? WW The US Food and Drug Administration (FDA) first approved lisocabtagene maraleucel (liso-cel; Breyanzi, Bristol Myers Squibb) on […]
Letter From the Editor
Letter From the Editor: The Cancer in Your County
Cancer in individuals is largely a random occurrence. Sure, some people have a strong family history of cancer or harbor a germline mutation in DNA repair […]